If you would like to have access to FUJIFILM Diosynth Biotechnologies' webinar, please fill out the form to the right. After filling out the form, a link to stream the webinar will be emailed to you.

Biopharmaceutical companies must make crucial decisions about their commercial manufacturing strategies despite having uncertain data about demand forecasts. This presentation will describe each strategy and the benefits of each in different scenarios.

• Production in facilities with multiple 20,000-L cell culture bioreactors is very efficient and will deliver low Cost of Goods, especially for high volume products.
• High-throughput single-use ballroom facilities provide a flexible alternative to large-scale stainless steel manufacturing plants and are well suited towards highly targeted therapeutics addressing niche markets.
• Continuous biomanufacturing strategies are now available which provide a high productivity yet flexible option to companies commercializing biologics.